国产亚洲欧美日韩俺去了,人妻无码久久精品,亚洲人成影院在线观看,亚洲AV永久无码精品表情包

美國iBio  
iBio 公司是一家生物制藥公司，該公司將其專(zhuān)利技術(shù) iBioLaunch?平臺商業(yè)化用于包括疫苗和治療性蛋白在內的生物制劑的生產(chǎn)。iBioLaunch 平臺使用綠色植物瞬時(shí)基因表達技術(shù)，以獲得較高的蛋白生產(chǎn)效率。其優(yōu)勢是降低資本和工藝成本，其技術(shù)非常適合于注重速度、可伸縮性和過(guò)負荷能力的傳染病應用。 iBio 公司的戰略是將其技術(shù)用于其自己的候選產(chǎn)品的開(kāi)發(fā)和制造，同時(shí)與企業(yè)客戶(hù)和政府客戶(hù)合作，減少他們在產(chǎn)品開(kāi)發(fā)過(guò)程中的成本并滿(mǎn)足低成本高質(zhì)量生物制劑制造系統的需要。iBio 公司擁有在 Fraunhofer 美國分子生物科技中心研發(fā)的技術(shù)，同時(shí)不斷支持技術(shù)的研發(fā)和完善，以廣泛應用于人類(lèi)醫療保健。

iBio, Inc. (IBIO:AMEX), a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBioLaunch? platform. The iBioLaunch platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines. It uses proprietary, transient gene expression in unmodified green plants instead of materials such as chicken eggs, mammalian and insect cells, transgenic plants, and human blood plasma required by other systems, to produce important biologic pharmaceuticals. This unique plant-based platform offers a number of significant advantages over other systems:

• Ability to synthesize complex proteins at which other systems have failed

• Simplicity, scalability and flexibility

• Reduced capital investment

• Lower operating costs

• Surge capacity

• Rapid production times – gene sequence to factory-scale protein harvest

• Eliminates the need of bioreactors

• Low risk of contamination by animal pathogens

iBio has a strong IP/technology portfolio and has been well established by more than nine years of applications development and $100 million in funding. Our current pipeline includes:

• Monoclonal antibodies

• Interferons & cytokines

• Enzymes for replacement therapy

• Plasma-derived proteins

• Growth factors

• Protease inhibitors

• Clotting factors

• Vaccines